These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32983297)

  • 1. Adrenal oligometastasis cured with stereotactic ablative radiotherapy.
    Malone J; Pantarotto JR; Tiberi D; Malone S
    Radiol Case Rep; 2020 Nov; 15(11):2266-2270. PubMed ID: 32983297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic ablative body radiation therapy for isolated pulmonary metastases from pancreatic cancer after metastectomy with positive margins: a case report.
    Alnsour A; Le H; Byrne A; Rodgers N; Roos D
    J Med Case Rep; 2023 Jun; 17(1):273. PubMed ID: 37312213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Radiotherapy for Oligometastasis.
    Otake S; Goto T
    Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30678111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative body radiotherapy for lung cancer.
    Franks KN; Jain P; Snee MP
    Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case of Metastatic Head and Neck Squamous Cell Carcinoma with Multiple Treatments Including Stereotactic Ablative Body Radiotherapy Alone for Oligometastases to the Parotid Gland.
    Sharrett J; Pederson A
    Cureus; 2015 Dec; 7(12):e438. PubMed ID: 26858919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Strategies in Stereotactic Radiotherapy for Oligometastases.
    Palma DA; Louie AV; Rodrigues GB
    Clin Cancer Res; 2015 Dec; 21(23):5198-204. PubMed ID: 26626571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.
    Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F
    Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
    Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
    Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenal Insufficiency following Stereotactic Ablative Radiotherapy (SAbR) of Adrenal Gland Metastases.
    Hamidi O; Miljanic M; Tumyan G; Christie A; Mirfakhraee S; Ali S; Dohopolski M; Gottumukkala S; Brugarolas J; Timmerman R; Hannan R
    Cancers (Basel); 2024 Sep; 16(18):. PubMed ID: 39335112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
    BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive Patients.
    Gandhidasan S; Ball D; Kron T; Bressel M; Shaw M; Chu J; Chander S; Wheeler G; Plumridge N; Chesson B; David S; Siva S
    Clin Oncol (R Coll Radiol); 2018 Mar; 30(3):178-184. PubMed ID: 29224900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
    Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
    Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.
    Saluja R; Cheung P; Zukotynski K; Emmenegger U
    Urol Oncol; 2016 May; 34(5):225-32. PubMed ID: 27008982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
    Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
    Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer.
    Wild AT; Yamada Y
    Visc Med; 2017 Mar; 33(1):54-61. PubMed ID: 28612018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.